Insider

Cardinal Health Inc

CAH Health Care · 3 analyses · 5 expectations tracked

Cardinal Health reported $67.5B in revenue (+5.5% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 5 open management expectations for this company.

Mentioned in recent filings: Ukraine Tariffs

What changed

Company history

October 2026

CARDINAL HEALTH INC: 12 recorded developments from 3 official sources in 2026-10.

  • 2026-09-21: The filing is a Definitive Additional Proxy Soliciting Materials filing (Form DEFA14A). Source
  • 2026-09-21: The filing is identified as a Definitive Proxy Statement. Source
  • 2026-09-21: The filing indicates that no filing fee is required. Source
  • 2026-09-21: The Board is focused on overseeing the priorities, investments, and decisions that support sustainable growth and long-term shareholder value. Source
  • 2026-09-21: During fiscal 2026, the company engaged closely with management on initiatives to strengthen and expand the Pharmaceutical and Specialty Solutions segment, accelerate growth across key growth areas, and drive operational excellence across the enterprise. Source
  • 2026-09-21: The Board maintained active oversight of the company's disciplined capital allocation framework, balancing investment of capital back into the business to enable profitable growth, focusing on balance sheet strength, returning capital to shareholders, and pursuing strategic acquisitions. Source
  • 2026-09-21: Cardinal Health is committed to thoughtful Board refreshment, leadership continuity, and succession planning to ensure the Board remains well-positioned to oversee the growing business and strategic priorities. Source
  • 2026-09-21: Gregory B. Kenny stepped down from his position as Board Chair and retired from the Board after more than 18 years of distinguished service to Cardinal Health. Source
  • 2026-09-21: Robert W. Musslewhite was appointed as Chair of the Human Resources and Compensation Committee. Source
  • 2026-09-21: During fiscal 2026, the Board transitioned oversight of the Enterprise Risk Management program to the Risk Oversight Committee. Source
  • 2026-10-01: On October 1, 2026, Cardinal Health, Inc. issued a news release announcing that it had entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. Source
  • 2026-10-01: The Company reaffirmed its previously issued fiscal year 2027 non-GAAP earnings per share (EPS) guidance range of $12.40 to $12.60 and its long-term non-GAAP EPS growth range guidance of 12% to 14%. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 5, 2026. SEC

LatestEarlierChange
Revenue quarter$67.5B$64B+5.5%
Operating income quarter$753M$668M+12.7%
Net income quarter$554M$450M+23.1%
Diluted EPS quarter$2.38$1.88+26.6%
Dividends per share quarter$0.52$0.51+1.0%
Operating cash flow quarter$1.4B$973M+43.7%
Cash and cash equivalents balance$5.3B$4.9B+8.4%

Next results expected around February 4, 2027 (estimate: the quarter ending about December 30, 2026 plus the 36 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

59.9Q4 '24*0.7%52.3Q1 '251.1%55.3Q2 '251%54.9Q3 '251.3%60.2Q4 '25*0.7%64Q1 '261%65.6Q2 '261.1%67.5Q1 '271.1%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%
Johnson & Johnson JNJ$25.4B+5.9%—

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Growth rates for fiscal year 2027 guidance are based upon adjusted fiscal year 2026 non-GAAP diluted EPS of $10.95, excluding the fiscal year 2026 benefit from IEEPA tariff refund.

    Said November 5, 2026 · Period named: fiscal year 2027 · Source · Our article

    Not yet checked against later reports.

  • Raised fiscal year 2027 guidance for non-GAAP diluted EPS to $12.80 to $13.00.

    Said November 5, 2026 · Period named: fiscal year 2027 · Source · Our article

    Not yet checked against later reports.

  • Anticipates completing the acquisition of AdaptHealth’s Diabetes Health business.

    Said November 5, 2026 · Period named: Q3 of fiscal 2027 · Source · Our article

    Not yet checked against later reports.

  • The Company reaffirmed its previously issued fiscal year 2027 non-GAAP earnings per share (EPS) guidance range of $12.40 to $12.60 and its long-term non-GAAP EPS growth range guidance of 12% to 14%.

    Said October 1, 2026 · Period named: fiscal year 2027 · Source · Our article

    Not yet checked against later reports.

  • In connection with the renewal, Cardinal Health has reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth1 ($12.40 to $12.60) and its long-term non-GAAP EPS growth rate guidance of 12% to 14%.

    Said October 1, 2026 · Period named: fiscal year 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
August 5, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock25,571,751$5,689,714,580-3.5%Q3 2026
State Street12,049,674$2,681,052,465+0.7%Q3 2026
Wellington Management9,866,422$2,195,278,898-33.6%Q3 2026
Geode Capital Management6,454,511$1,430,568,319-0.3%Q3 2026
Norges Bank (Norway's sovereign fund)3,726,422$885,248,810—Q2 2026
Fidelity (FMR)1,837,270$408,792,727-11.1%Q3 2026
D. E. Shaw & Co.872,765$194,190,213+58.6%Q3 2026
Renaissance Technologies835,700$185,943,250+51.9%Q3 2026
Millennium Management694,396$154,503,110+172.6%Q3 2026
Citadel Advisors251,321$55,918,923+29.6%Q3 2026
Bridgewater Associates128,388$28,566,330-2.8%Q3 2026
Two Sigma Investments1,400$332,584-99.7%Q2 2026
T. Rowe Price1,442,680$320,998-35.7%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.